You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
一品紅(300723.SZ):全資子公司注射用蘭索拉唑獲批上市
格隆匯 11-08 11:49

格隆匯11月8日丨一品紅(300723.SZ)公佈,公司全資子公司廣州一品紅製藥有限公司於近日收到國家藥監局核准簽發的關於注射用蘭索拉唑的《藥品註冊證書》。注射用蘭索拉唑用於口服療法不適用的伴有出血的胃、十二指腸潰瘍、急性應激潰瘍、急性胃黏膜損傷,是國家醫保乙類產品。

蘭索拉唑屬於質子泵抑制劑(PPI),是繼奧美拉唑之後的新一代質子泵抑制劑。因其特異性高,抑酸作用強而時間久,症狀消失快,潰瘍癒合率高,不良反應少,而且經濟性好,已成為治療與酸有關的消化系統功能紊亂性疾病的有效藥物,具有重要的臨牀應用價值。

米內網數據顯示,2020年在中國城市公立醫院、縣級公立醫院、城市社區中心及鄉鎮衞生院(簡稱中國公立醫療機構)終端治療消化性潰瘍藥品種TOP20中,蘭索拉唑排在第五位,銷售額超過30億元。

公司獲批的注射用蘭索拉唑是國內按化學藥品新註冊分類申報,視同通過一致性評價。

公司表示,此次獲得注射用蘭索拉唑註冊證書,標誌着公司具備了在國內市場銷售該藥品的資格,將進一步豐富了公司產品管線和品類,增強公司在慢病領域的競爭力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account